Bromfenac

Bromfenac

SCHEMBL34411

Nc1c(CC(=O)O)cccc1C(=O)c1ccc(Br)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

PTGS1PTGS2

The experimentally established mechanism targets of Bromfenac. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
PTGS1 known ✓ P23219 1/20 1.00
PTGS2 known ✓ P35354 1/20 1.00
ABCB11 O95342 1/20 1.00
LMNA P02545 1/20 1.00
ADORA1 P30542 1/20 1.00
AKR1C3 P42330 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromfenac SCHEMBL14861906 1.00 ABCB11 (1.00) ABCB11LMNAPTGS1ADORA1PTGS2
Bromfenac SCHEMBL28420990 0.99 ABCB11 (0.97) ABCB11LMNAPTGS1ADORA1PTGS2
Bromfenac SCHEMBL28429368 0.99 ABCB11 (0.97) ABCB11LMNAPTGS1ADORA1PTGS2
Bromfenac SCHEMBL28895435 0.99 ABCB11 (0.97) ABCB11LMNAPTGS1ADORA1PTGS2
Bromfenac SCHEMBL28429415 0.99 ABCB11 (0.97) ABCB11LMNAPTGS1ADORA1PTGS2
Bromfenac SCHEMBL57092 0.99 ABCB11 (0.97) ABCB11LMNAPTGS1ADORA1PTGS2
Bromfenac SCHEMBL57090 0.99 ABCB11 (0.97) ABCB11LMNAPTGS1ADORA1PTGS2
Bromfenac SCHEMBL15968905 0.99 ABCB11 (0.97) ABCB11LMNAPTGS1ADORA1PTGS2
Bromfenac SCHEMBL28429917 0.99 ABCB11 (0.97) ABCB11LMNAPTGS1ADORA1PTGS2
Bromfenac SCHEMBL4603047 0.99 ABCB11 (0.97) ABCB11LMNAPTGS1ADORA1PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 14427 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4724839-A2 CONTACT LENSES INCLUDING MEDICAMENTS AND METHODS OF MAKING AND USING SAME INCLUDING SLOW RELEASE OF GLAUCOMA TREATING DRUGS AND COMFORT ENHANCING DRUGS Mediprint Ophthalmics Inc. (US) 2026-04-15 EP claimed
US-12594351-B2 Methods for increasing shelf-life of ophthalmic pharmaceutical compositions HARROW IP LLC (US) 2026-04-07 US claimed
US-20260090984-A1 CONTACT LENSES INCLUDING MEDICAMENTS AND METHODS OF MAKING AND USING SAME INCLUDING SLOW RELEASE OF GLAUCOMA TREATING DRUGS AND COMFORT ENHANCING DRUGS MEDIPRINT OPHTHALMICS INC. (US) 2026-04-02 US claimed
US-20260091018-A1 COMBINATION PREPARATION CONTAINING HETEROCYCLIDENE ACETAMIDE DERIVATIVE SENJU PHARMACEUTICAL CO., LTD. (JP) 2026-04-02 US claimed
US-20260076872-A1 POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME SIO2 MEDICAL PRODUCTS LLC (US) 2026-03-19 US claimed
US-12569451-B2 Bio-inspired tissue-adhesive hydrogel patch and uses thereof Cellartgen Inc. (KR) 2026-03-10 US claimed
US-12527767-B2 Eye drops to treat chemically induced corneal damage THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) 2026-01-20 US claimed
US-20260000741-A1 METHOD OF AMELIORATING A PRO-INFLAMMATORY IMMUNOPHENOTYPE IN FARBER DISEASE SUBJECTS BY REPEATED ADMINISTRATION OF A RECOMBINANT HUMAN ACID CERAMIDASE ACERAGEN INC (US) 2026-01-01 US claimed
US-20250381201-A1 COMPOSITIONS AND METHODS FOR TREATING EYES AND METHODS OF PREPARATION OCULAR SCIENCE INC (US) 2025-12-18 US claimed
US-20250345274-A1 ALKALI METAL SALT COMBINATIONS OF INCOMPATIBLE ACTIVE PHARMACEUTICAL INGREDIENTS HALEON US HOLDINGS LLC (US) 2025-11-13 US claimed
EP-0739197-A1 PRESERVED OPHTHALMIC DRUG COMPOSITIONS CONTAINING POLYMERIC QUATERNARY AMMONIUM COMPOUNDS ALCON LABORATORIES, INC. (US) 1996-10-30 EP claimed
WO-1996030022-A1 TOPICAL OPHTHALMIC FORMULATIONS COMPRISING AN ACIDIC DRUG, VITAMIN E TPGS, BENZALKONIUM CHLORIDE AND CAFFEINE ALCON LABORATORIES, INC. (US) 1996-10-03 WO claimed
EP-0734248-A1 IMPROVED INTRAOCULAR IRRIGATING SOLUTION CONTAINING NON-STEROIDAL ANTIINFLAMMATORY AGENT ALCON LABORATORIES, INC. (US) 1996-10-02 EP claimed
US-5558876-A IMPROVED STABILITY AND COMFORT, VITAMIN E TOCOPHEROL POLYETHYLENE GLYCOL SUCCINATE ALCON LABORATORIES, INC. (US) 1996-09-24 US claimed
WO-1996020187-A2 ESTERS AND AMIDES OF NON-STEROIDAL ANTI-INFLAMMATORY CARBOXYLIC ACIDS WHICH MAY BE USED AS ANTI-OXIDANTS, 5-LIPOXYGENASE INHIBITORS AND NON-STEROIDAL ANTI-INFLAMMATORY PRODUCTS ALCON LABORATORIES, INC. (US) 1996-07-04 WO claimed
WO-1996014829-A1 PRESERVED OPHTHALMIC DRUG COMPOSITIONS CONTAINING POLYMERIC QUATERNARY AMMONIUM COMPOUNDS ALCON LABORATORIES, INC. (US) 1996-05-23 WO claimed
WO-1995016435-A2 IMPROVED INTRAOCULAR IRRIGATING SOLUTION CONTAINING NON-STEROIDAL ANTIINFLAMMATORY AGENT ALCON LABORATORIES, INC. (US) 1995-06-22 WO claimed
EP-0221753-B1 TRANSDERMAL TREATMENT FOR PAIN AND INFLAMMATION WITH 2-AMINO-3-AROYLBENZENEACETIC ACIDS, SALTS AND ESTERS A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) (US) 1992-01-08 EP claimed
US-4683242-A Transdermal treatment for pain and inflammation with 2-amino-3-aroylbenzeneacetic acids, salts and esters A. H. ROBINS COMPANY, INCORPORATED (US) 1987-07-28 US claimed
EP-0221753-A2 Transdermal treatment for pain and inflammation with 2-amino-3-aroylbenzeneacetic acids, salts and esters A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) (US) 1987-05-13 EP claimed